Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 3/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1046277 | 0.87 | GRIA1 (0.44) | GRIA1GRIA2GRIA3GRIA4P2RX7 | |
| Iodide SCHEMBL9623168 | 0.75 | PTGER4 (0.39) | GRIA1GRIA2GRIA3GRIA4ALDH1A1 | |
| Bromide SCHEMBL11597934 | 0.73 | GRIA1 (0.35) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL16525690 | 0.62 | GRIA1 (0.38) | GRIA1GRIA2GRIA3GRIA4KDM4E | |
| SCHEMBL29007323 | 0.62 | KDM4E (0.41) | KDM4EALDH1A1GAASLC6A2SLC6A4 | |
| Bromide SCHEMBL29283560 | 0.61 | KDM4E (0.40) | KDM4EALDH1A1GAASLC6A2SLC6A4 | |
| SCHEMBL17417947 | 0.60 | SNCA (0.45) | PKM | |
| SCHEMBL17417948 | 0.60 | SNCA (0.45) | PKM | |
| SCHEMBL1412808 | 0.60 | MEN1 (0.34) | GRIA1GRIA2GRIA3GRIA4ALDH1A1 | |
| SCHEMBL9972944 | 0.57 | L3MBTL1 (0.50) | KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867197-B1 | Method of targeting conjugate molecules to mitochondria | MITOKOR (US) | 2005-03-15 | — | — | US | disclosed |
| US-20030087858-A1 | Diagnostic and therapeutic compositions for alzheimer's disease | MITOKOR (US) | 2003-05-08 | — | — | US | disclosed |
| US-6171859-B1 | DEFECTIVE CYTOCHROME C OXIDASE; DIAGNOSING ALZHEIMER*S DISEASE | MITOKOR | 2001-01-09 | — | — | US | disclosed |
| US-6146831-A | CYBRID CELL LINE OF CULTURED CELLS HAVING GENOMIC AND MITOCHONDRIAL NUCLEIC ACIDS OF DIFFERENT BIOLOGICAL ORIGINS; FOR DRUG SCREENING AND EVALUATION OF THERAPY | MITOKOR (US) | 2000-11-14 | — | — | US | disclosed |
| EP-0751951-A4 | DIAGNOSIS, THERAPY AND CELLULAR AND ANIMAL MODELS FOR DISEASES ASSOCIATED WITH MITOCHONDRIAL DEFECTS | MITOKOR (US) | 2000-05-03 | — | — | EP | disclosed |
| EP-0939832-A1 | MITOCHONDRIAL DNA MUTATIONS THAT SEGREGATE WITH LATE ONSET DIABETES MELLITUS | Mitokor (US) | 1999-09-08 | — | — | EP | disclosed |
| US-5840493-A | DIAGNOSIS OF LATE ONSET DIABETES BY DETECTION OF MUTATIONS IN ADENOSINE TRIPHOSPHATE SYNTHASE OR TRANSFER RNA (LYS) GENES IN A BIOLOGICAL SAMPLE; LABELLED NUCLEOTIDE SEQUENCES AS DETECTORS; ACCURACY | MITOKOR (US) | 1998-11-24 | — | — | US | disclosed |
| WO-1998017826-A1 | MITOCHONDRIAL DNA MUTATIONS THAT SEGREGATE WITH LATE ONSET DIABETES MELLITUS | MITOKOR (US) | 1998-04-30 | — | — | WO | disclosed |
| EP-0751951-A1 | DIAGNOSIS, THERAPY AND CELLULAR AND ANIMAL MODELS FOR DISEASES ASSOCIATED WITH MITOCHONDRIAL DEFECTS | Mitokor (US) | 1997-01-08 | — | — | EP | disclosed |
| WO-1995026973-A1 | DIAGNOSIS, THERAPY AND CELLULAR AND ANIMAL MODELS FOR DISEASES ASSOCIATED WITH MITOCHONDRIAL DEFECTS | MITOKOR (US) | 1995-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087858-A1 | Diagnostic and therapeutic compositions for alzheimer's disease | COX5A, MT-CO3, COX6A1 | GRIA1 1843/4885GRIA2 1621/4885GRIA3 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.